PLGA-encapsulated perfluorocarbon nanoparticles for simultaneous visualization of distinct cell populations by ¹⁹F MRI

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Srinivas M, Aarntzen EH, Bulte JW et al. Imaging of cellular therapies. Adv. Drug Deliv. Rev. 62(11), 1080–1093 (2010).•• Reviews the role of imaging to optimize cell therapy.
  Medline CASGoogle Scholar
• 2 Ahrens ET, Bulte JW. Tracking immune cells in vivo using magnetic resonance imaging. Nat. Rev. Immunol. 13(10), 755–763 (1038) (2013).• Describes the different techniques for cell tracking using MRI.
  Medline CASGoogle Scholar
• 3 De Vries IJ, Lesterhuis WJ, Barentsz JO et al. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat. Biotechnol. 23(11), 1407–1413 (2005).• The first published work using MRI for cell tracking in the clinic.
  Medline CASGoogle Scholar
• 4 Srinivas M, Heerschap A, Ahrens ET, Figdor CG, De Vries IJ. (¹⁹) F MRI for quantitative in vivo cell tracking. Trends Biotechnol. 28(7), 363–370 (2010).•• Reviews the general pros and cons of 19F MRI for cell tracking.
  Medline CASGoogle Scholar
• 5 Cametti M, Crousse B, Metrangolo P, Milani R, Resnati G. The fluorous effect in biomolecular applications. Chem. Soc. Rev. 41(1), 31–42 (2012).
  Medline CASGoogle Scholar
• 6 Srinivas M, Boehm-Sturm P, Figdor CG, De Vries IJ, Hoehn M. Labeling cells for in vivo tracking using (¹⁹)F MRI. Biomaterials 33(34), 8830–8840 (2012).
  Medline CASGoogle Scholar
• 7 Ahrens ET, Helfer BM, O'hanlon CF, Schirda C. Clinical cell therapy imaging using a perfluorocarbon tracer and fluorine-¹⁹ MRI. Magn. Reson. Med. 72 (6), 1696–1701 (2014).
  Medline CASGoogle Scholar
• 8 Helfer BM, Balducci A, Nelson AD et al. Functional assessment of human dendritic cells labeled for in vivo (¹⁹) F magnetic resonance imaging cell tracking. Cytotherapy 12(2), 238–250 (2010).
  Medline CASGoogle Scholar
• 9 Srinivas M, Cruz LJ, Bonetto F, Heerschap A, Figdor CG, De Vries IJ. Customizable, multi-functional fluorocarbon nanoparticles for quantitative in vivo imaging using ¹⁹F MRI and optical imaging. Biomaterials 31(27), 7070–7077 (2010).
  Medline CASGoogle Scholar
• 10 Hahn T, Kozerke S, Schwizer W, Fried M, Boesiger P, Steingoetter A. Visualization and quantification of intestinal transit and motor function by real-time tracking of ¹⁹ F labeled capsules in humans. Magn. Reson. Med. 66(3), 812–820 (2011).
  MedlineGoogle Scholar
• 11 Srinivas M, Cruz LJ, Bonetto F, Heerschap A, Figdor CG, De Vries IJ. Customizable, multi-functional fluorocarbon nanoparticles for quantitative in vivo imaging using 19F MRI and optical imaging. Biomaterials 31(27), 7070–7077 (2010).
  MedlineGoogle Scholar
• 12 Bonetto F, Srinivas M, Weigelin B et al. A large-scale (¹⁹) F MRI-based cell migration assay to optimize cell therapy. NMR Biomed. 25(9), 1095–1103 (2012).
  Medline CASGoogle Scholar
• 13 Di Corato R, Gazeau F, Le Visage C et al. High-resolution cellular MRI: gadolinium and iron oxide nanoparticles for in-depth dual-cell imaging of engineered tissue constructs. ACS Nano 7(9), 7500–7512 (2013).
  Medline CASGoogle Scholar
• 14 Partlow KC, Chen J, Brant JA et al. ¹⁹ F magnetic resonance imaging for stem/progenitor cell tracking with multiple unique perfluorocarbon nanobeacons. FASEB J. 21(8), 1647–1654 (2007).• Describes the use of multiple 19F resonances for cell tracking, but this could only be done using spectroscopic imaging.
  Medline CASGoogle Scholar
• 15 Lim YT, Noh YW, Cho JH et al. Multiplexed imaging of therapeutic cells with multispectrally encoded magnetofluorescent nanocomposite emulsions. J. Am. Chem. Soc. 131(47), 17145–17154 (2009).
  Medline CASGoogle Scholar
• 16 Tel J, Aarntzen EH, Baba T et al. Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. Cancer Res. 73(3), 1063–1075 (2013).
  Medline CASGoogle Scholar
• 17 Lou Y, Liu C, Kim GJ, Liu YJ, Hwu P, Wang G. Plasmacytoid dendritic cells synergize with myeloid dendritic cells in the induction of antigen-specific antitumor immune responses. J. Immunol. 178(3), 1534–1541 (2007).
  Medline CASGoogle Scholar
• 18 Piccioli D, Sammicheli C, Tavarini S et al. Human plasmacytoid dendritic cells are unresponsive to bacterial stimulation and require a novel type of cooperation with myeloid dendritic cells for maturation. Blood 113(18), 4232–4239 (2009).
  Medline CASGoogle Scholar
• 19 Bakdash G, Schreurs I, Schreibelt G, Tel J. Crosstalk between dendritic cell subsets and implications for dendritic cell-based anticancer immunotherapy. Expert Rev. Clin. Immunol. 10(7), 915–926 (2014).• Describes the synergy that develops when using multiple therapeutic cell subsets.
  Medline CASGoogle Scholar
• 20 Schreibelt G, Klinkenberg LJ, Cruz LJ et al. The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3+ myeloid dendritic cells. Blood 119(10), 2284–2292 (2012).
  Medline CASGoogle Scholar
• 21 Tel J, Benitez-Ribas D, Hoosemans S et al. DEC-205 mediates antigen uptake and presentation by both resting and activated human plasmacytoid dendritic cells. Eur. J. Immunol. 41(4), 1014–1023 (2011).
  Medline CASGoogle Scholar
• 22 Perro A, Reculusa S, Ravaine S, Bourgeat-Lami EB, Duguet E. Design and synthesis of Janus micro- and nanoparticles. J. Mater. Chem. 15(35–36), 3745–3760 (2005).
  CASGoogle Scholar
• 23 Martin-Banderas L, Duran-Lobato M, Munoz-Rubio I, Alvarez-Fuentes J, Fernandez-Arevalo M, Holgado MA. Functional PLGA NPs for oral drug delivery: recent strategies and developments. Mini. Rev. Med. Chem. 13(1), 58–69 (2013).
  Medline CASGoogle Scholar
• 24 Ungaro F, D'angelo I, Miro A, La Rotonda MI, Quaglia F. Engineered PLGA nano- and micro-carriers for pulmonary delivery: challenges and promises. J. Pharm. Pharmacol. 64(9), 1217–1235 (2012).
  Medline CASGoogle Scholar
• 25 Misra A, Urban MW. Acorn-shape polymeric nano-colloids: synthesis and self-assembled films. Macromol. Rapid Comm. 31(2), 119–127 (2010).
  Medline CASGoogle Scholar
• 26 Tel J, Van Der Leun AM, Figdor CG, Torensma R, De Vries IJ. Harnessing human plasmacytoid dendritic cells as professional APCs. Cancer Immunol. Immunother. 61(8), 1279–1288 (2012).
  Medline CASGoogle Scholar
• 27 Tel J, Torensma R, Figdor CG, De Vries IJ. IL-4 and IL-13 alter plasmacytoid dendritic cell responsiveness to CpG DNA and herpes simplex virus-1. J. Invest. Dermatol. 131(4), 900–906 (2011).
  Medline CASGoogle Scholar
• 28 Rettig L, Haen SP, Bittermann AG et al. Particle size and activation threshold: a new dimension of danger signaling. Blood 115(22), 4533–4541 (2010).
  Medline CASGoogle Scholar
• 29 Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Preat V. PLGA-based nanoparticles: an overview of biomedical applications. J. Control. Release 161(2), 505–522 (2012).
  Medline CASGoogle Scholar
• 30 Sah H, Thoma LA, Desu HR, Sah E, Wood GC. Concepts and practices used to develop functional PLGA-based nanoparticulate systems. Int. J. Nanomedicine 8, 747–765 (2013).
  MedlineGoogle Scholar
• 31 De Chickera SN, Snir J, Willert C et al. Labelling dendritic cells with SPIO has implications for their subsequent in vivo migration as assessed with cellular MRI. Contrast Media Mol. Imaging 6(4), 314–327 (2011).
  Medline CASGoogle Scholar
• 32 Morel PA, Srinivas M, Turner MS et al. Gene expression analysis of dendritic cells that prevent diabetes in NOD mice: analysis of chemokines and costimulatory molecules. J. Leukoc. Biol. 90(3), 539–550
  MedlineGoogle Scholar
• 33 Bonetto F, Srinivas M, Heerschap A et al. A novel (¹⁹) F agent for detection and quantification of human dendritic cells using magnetic resonance imaging. Int. J. Cancer 129(2), 365–373 (2011).
  Medline CASGoogle Scholar